BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
11/15/2023 1:46:53 PM | Browse: 81 | Download: 175
 |
Received |
|
2023-07-06 07:09 |
|
Peer-Review Started |
|
2023-07-06 07:11 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2023-09-05 20:03 |
|
Revised |
|
2023-09-15 09:37 |
|
Second Decision |
|
2023-09-28 02:49 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Company Editor-in-Chief |
|
2023-09-28 05:55 |
|
Articles in Press |
|
2023-09-28 05:55 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2023-11-03 08:21 |
|
Publish the Manuscript Online |
|
2023-11-15 13:46 |
| ISSN |
1948-5204 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Oncology |
| Manuscript Type |
Case Report |
| Article Title |
Response of cholangiocarcinoma with epigastric metastasis to lenvatinib plus sintilimab: A case report and review of literature
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Wen-Hui Luo, Shao-Jun Li and Xue-Feng Wang |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Xue-Feng Wang, MD, Associate Chief Physician, Doctor, The Second Department of Hepatobiliary Surgery, Yantai Yuhuangding Hospital, No. 20 Yuhuangding East Road, Zhifu District, Yantai 264000, Shandong Province, China. seasonslo@126.com |
| Key Words |
Cholangiocarcinoma; Immune-checkpoint-inhibitor; Lenvatinib; Sintilimab; Epigastric metastasis; Immunotherapy; Case report |
| Core Tip |
Cholangiocarcinoma (CCA) is a highly lethal hepatobiliary neoplasm. This report presents a case with advanced CCA who received immunotherapy, revealing differences in treatment responses between intrahepatic vs. extrahepatic epigastric metastatic sites. This hitherto unreported phenomenon prompted us to investigate the differential outcomes of these metastatic patterns following treatment with lenvatinib combined with sintilimab, culminating in a summary report elucidating potential underlying mechanisms. |
| Publish Date |
2023-11-15 13:46 |
| Citation |
Luo WH, Li SJ, Wang XF. Response of cholangiocarcinoma with epigastric metastasis to lenvatinib plus sintilimab: A case report and review of literature. World J Gastrointest Oncol 2023; 15(11): 2033-2040 |
| URL |
https://www.wjgnet.com/1948-5204/full/v15/i11/2033.htm |
| DOI |
https://dx.doi.org/10.4251/wjgo.v15.i11.2033 |
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
